DK3043816T3 - Anti-b7-h1-antistoffer til behandling af tumorer - Google Patents

Anti-b7-h1-antistoffer til behandling af tumorer

Info

Publication number
DK3043816T3
DK3043816T3 DK14766962.6T DK14766962T DK3043816T3 DK 3043816 T3 DK3043816 T3 DK 3043816T3 DK 14766962 T DK14766962 T DK 14766962T DK 3043816 T3 DK3043816 T3 DK 3043816T3
Authority
DK
Denmark
Prior art keywords
tumors
antibodies
treatment
Prior art date
Application number
DK14766962.6T
Other languages
English (en)
Inventor
Rajesh Narwal
David Fairman
Paul Robbins
Meina Liang
Amy Schneider
Carlos Chavez
Carina Herl
Min Pak
Hong Lu
Marlon Rebelatto
Keith Steele
Anmarie Boutrin
Li Shi
Shengyan Hong
Brandon Higgs
Lorin Roskos
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK3043816T3 publication Critical patent/DK3043816T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14766962.6T 2013-09-11 2014-09-11 Anti-b7-h1-antistoffer til behandling af tumorer DK3043816T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361876509P 2013-09-11 2013-09-11
US201461971212P 2014-03-27 2014-03-27
US201461978401P 2014-04-11 2014-04-11
US201462003349P 2014-05-27 2014-05-27
PCT/EP2014/069425 WO2015036499A1 (en) 2013-09-11 2014-09-11 Anti-b7-h1 antibodies for treating tumors

Publications (1)

Publication Number Publication Date
DK3043816T3 true DK3043816T3 (da) 2019-10-14

Family

ID=51570487

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14766962.6T DK3043816T3 (da) 2013-09-11 2014-09-11 Anti-b7-h1-antistoffer til behandling af tumorer

Country Status (19)

Country Link
US (3) US10336823B2 (da)
EP (2) EP3043816B1 (da)
JP (5) JP6550053B2 (da)
KR (5) KR102329584B1 (da)
CN (2) CN105873606B (da)
AU (3) AU2014320343B2 (da)
BR (1) BR112016005303A2 (da)
CA (1) CA2923499A1 (da)
DK (1) DK3043816T3 (da)
ES (1) ES2749744T3 (da)
HU (1) HUE046674T2 (da)
IL (5) IL292193B2 (da)
MX (1) MX370818B (da)
NZ (2) NZ718821A (da)
PL (1) PL3043816T3 (da)
RU (1) RU2701327C2 (da)
SA (1) SA516370713B1 (da)
TW (1) TWI643633B (da)
WO (1) WO2015036499A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
NZ718821A (en) * 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
EP3149043A1 (en) * 2014-05-29 2017-04-05 Medimmune Limited Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
ES2791950T3 (es) 2015-02-03 2020-11-06 Ventana Med Syst Inc Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US20180147279A1 (en) * 2015-04-23 2018-05-31 Medimmune Limited Combination therapy for non-small cell lung cancer positive for egfr mutation
RS61152B2 (sr) * 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
AU2017269675A1 (en) * 2016-05-26 2019-01-17 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for cancer treatment
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
JP7383620B2 (ja) * 2018-01-31 2023-11-20 セルジーン コーポレイション 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
CN119899267A (zh) * 2018-03-22 2025-04-29 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 拮抗性pd-1、pd-l1和lag-3结合蛋白
SG11202107317WA (en) 2019-01-18 2021-08-30 Dracen Pharmaceuticals Inc Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
AU2020212767B2 (en) * 2019-01-25 2025-01-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
CN114269763A (zh) 2019-03-26 2022-04-01 美国密歇根州立大学试剂中心 Stat3的小分子降解剂
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
US20220304984A1 (en) 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
KR20220026575A (ko) * 2019-06-25 2022-03-04 시티 오브 호프 Pdl1 양성 nk 세포 암 치료
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
CA3138560A1 (en) 2019-07-16 2021-01-21 Shaomeng Wang Imidazopyrimidines as eed inhibitors and the use thereof
CA3151824A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
CN114430746B (zh) * 2019-09-25 2023-09-01 上海药明生物技术有限公司 新型抗pd-l1抗体
US12522623B2 (en) 2020-03-26 2026-01-13 Regents Of The University Of Michigan Small molecule STAT protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
JP7846686B2 (ja) 2020-10-02 2026-04-15 ドラセン ファーマシューティカルズ インコーポレイテッド 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
MX2023011332A (es) * 2021-03-26 2023-10-03 Astrazeneca Ab Tratamientos combinados para el melanoma.
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
AU2002258941A1 (en) * 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2009089149A1 (en) * 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN101693562A (zh) * 2009-10-21 2010-04-14 山东大学 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂
NZ628923A (en) * 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
NZ718821A (en) * 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
PT3142751T (pt) * 2014-05-13 2019-10-25 Medimmune Ltd Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
US20170320954A1 (en) * 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS

Also Published As

Publication number Publication date
IL244422A0 (en) 2016-04-21
TW201605472A (zh) 2016-02-16
KR102661249B1 (ko) 2024-04-25
KR20210143932A (ko) 2021-11-29
JP6550053B2 (ja) 2019-07-24
JP2021006537A (ja) 2021-01-21
IL292193A (en) 2022-06-01
WO2015036499A1 (en) 2015-03-19
MX2016002826A (es) 2016-09-13
EP3043816B1 (en) 2019-08-14
US10336823B2 (en) 2019-07-02
EP3043816A1 (en) 2016-07-20
HUE046674T2 (hu) 2020-03-30
KR102329584B1 (ko) 2021-11-22
AU2014320343B2 (en) 2020-05-28
CN105873606B (zh) 2020-12-29
TWI643633B (zh) 2018-12-11
EP3656398A1 (en) 2020-05-27
RU2016113341A (ru) 2017-10-16
AU2024203898A1 (en) 2024-07-04
MX370818B (es) 2020-01-08
AU2020223728B2 (en) 2024-03-07
US20210171639A1 (en) 2021-06-10
KR20240056664A (ko) 2024-04-30
IL321966A (en) 2025-09-01
JP7342167B2 (ja) 2023-09-11
US10829557B2 (en) 2020-11-10
RU2701327C2 (ru) 2019-09-25
ES2749744T3 (es) 2020-03-23
IL313188B2 (en) 2025-12-01
RU2019128452A (ru) 2019-10-24
JP7119037B2 (ja) 2022-08-16
AU2020223728A1 (en) 2020-09-17
IL292193B2 (en) 2024-11-01
BR112016005303A2 (pt) 2017-09-12
KR20260008188A (ko) 2026-01-15
SA516370713B1 (ar) 2019-03-10
US20160222120A1 (en) 2016-08-04
JP2016530323A (ja) 2016-09-29
IL313188A (en) 2024-07-01
NZ718821A (en) 2022-07-01
CA2923499A1 (en) 2015-03-19
RU2016113341A3 (da) 2018-05-30
IL244422B (en) 2020-05-31
IL274462A (en) 2020-06-30
JP2022065100A (ja) 2022-04-26
CN112546217A (zh) 2021-03-26
IL274462B (en) 2022-05-01
IL313188B1 (en) 2025-08-01
PL3043816T3 (pl) 2020-03-31
JP2019163269A (ja) 2019-09-26
US20190338033A1 (en) 2019-11-07
NZ757060A (en) 2022-07-01
CN105873606A (zh) 2016-08-17
KR20220162843A (ko) 2022-12-08
CN112546217B (zh) 2025-04-29
IL292193B1 (en) 2024-07-01
AU2014320343A1 (en) 2016-04-21
KR20160044030A (ko) 2016-04-22
US11827706B2 (en) 2023-11-28
JP2023166474A (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3508502T5 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK2968208T3 (da) Behandling af kataplexi
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3068800T3 (da) FcRn-specifikke antistoffer
LT3007726T (lt) Tautopatijos gydymo būdai
DK3014279T3 (da) Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida
DK3511004T3 (da) Kombineret præparat til behandling af cancer